middle.news
Why Did Immutep Halt Its Pivotal NSCLC Trial After Early Data?
9:06am on Friday 13th of March, 2026 AEDT
•
Biotechnology
Read Story
Why Did Immutep Halt Its Pivotal NSCLC Trial After Early Data?
9:06am on Friday 13th of March, 2026 AEDT
Key Points
TACTI-004 Phase III trial stopped due to futility recommendation
Enrollment halted; orderly wind down underway
Eftilagimod alfa’s efficacy in NSCLC questioned despite prior successes
Cash runway extended beyond previous Q2 2027 guidance
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Immutep (ASX:IMM)
OPEN ARTICLE